HPV – Page 43 – Oral Cancer News

Oral cancer screenings a must, say malpractice attorneys

Source: Dr.Bicuspid.com By: Donna Domino March 10, 2011 -- The patient was insistent: All she wanted was to get her teeth whitened for an upcoming high school reunion. She came in for the $99 Internet special the dentist had run and mentioned a sore on her tongue, but she said it was recent, attributing it to a tongue-biting habit. The dentist did the procedure but advised the patient that she needed a follow-up oral exam. The patient eventually went to an oral surgeon who diagnosed the young mother with terminal tongue cancer. She sued the dentist who did the teeth whitening for malpractice, for missing her oral cancer. That case, Tale of the Tainted Tongue, was dramatized at the recent Chicago Dental Society Midwinter Meeting in a session highlighting the growing number of malpractice suits over missed oral cancer screenings. Anne Oldenburg, an attorney with Alholm, Monahan, Klauke, Hay & Oldenburg, which specializes in dental malpractice cases, participated in the mock trial. Ten years ago she didn't have many such cases, she told DrBicuspid.com. But that scenario has changed dramatically in recent years, she said, noting that she is currently involved in three dental malpractice cases. The mock trial was similar to a previous lawsuit she handled, in which a young man in his 40s died. "It was oral cancer that was clearly missed," Oldenburg recalled. The family settled for $750,000 because the children didn't want to go through the litigation process, but many death cases can reach $1 million [...]

Oral Cancer Foundation News Team - A2011-03-14T11:58:49-07:00March, 2011|OCF In The News, Oral Cancer News|

HPV prevalence in men

Source: The Lancet, Volume 377, Issue 9769, Pages 881 - 883, 12 March 2011 Authors: Anna Giuliano et al. In The Lancet, Anna Giuliano and colleagues1 present a prospective study (HPV in Men [HIM]) of the incidence and clearance of human papillomavirus (HPV) infections in men. They also report on male sexual behavior, which determines HPV incidence and clearance. The epidemiology of HPV infections in men is not well understood and thus the results are of substantial interest. The results bring to light important new information, and draw attention to differences between the natural histories of male and female HPV infections, and the need for further studies to better define HPV transmission, progression to disease, and epithelial sites in men. Because HPV infection in men greatly affects disease risk in women,2 transmission and protection are important topics. However, circumcision and condom use have not been clearly shown to fully protect against either HPV acquisition or clearance in male genital sites,3, 4 which questions their value in preventing infection in men and transmission to female partners. Understanding male HPV infection is important to minimize anxiety and the health-care costs associated with genital warts, penile cancer treatment, and morbidity in men, in addition to addressing the acknowledged public health concern created by HPV infection in women. The HIM data on HPV incidence and clearance should be exploited to elaborate prevention guidance, and to minimize transmission and to aid management and associated concerns for couples. Because most HPV infections in men are asymptomatic, [...]

Oral Cancer Foundation News Team - A2011-03-12T11:50:39-07:00March, 2011|Oral Cancer News|

HIM study looks at HPV infection and clearance in men

Medscape Oncology News By Nick Mulcahy March 1, 2011 — Half of all the men participating in a natural history study of human papillomavirus (HPV) were infected with some strain of HPV at some point during study period, according to the results of a new study published online March 1 in the Lancet. The HPV in Men (HIM) study, led by Anna Giuliano, PhD, from the H. Lee Moffitt Cancer Center in Tampa, Florida, followed 1159 adult males for a median follow-up of 27.5 months. However, the prevalence of viral types for which there is a prophylactic vaccine is low — 6% for HPV16 and 2% for HPV18 (the 2 oncogenic types), and 7% for HPV6 and 1% for HPV11 (the 2 nononcogenic types). Data on HPV incidence and clearance from the HIM study have immediate uses, suggests the author of an editorial accompanying the study. "The HIM data on HPV incidence and clearance should be exploited to elaborate prevention guidance, and to minimize transmission and to aid management and associated concerns for couples," says editorialist Joseph Monsonego, MD, from the Institute of the Cervix in Paris, France. Men transmitting HPV to women is especially concerning, writes Dr. Monsonego, because "extrapolation from the HIM data strongly suggests that the natural history of HPV is different in men and women, with high infection and low disease rates in men and low infection and high disease rates in women." However, he points out that "the cost–benefit ratio of vaccinating men to protect women from [...]

Oral Cancer Foundation News Team - A2011-03-04T17:37:35-07:00March, 2011|Oral Cancer News|

Oral sex now main cause of oral cancer: Who faces biggest risk?

Source: www.cbsnews.com Author: David W Freeman What's the leading cause of oral cancer? Smoking? Heavy drinking? Actually, it's oral sex. Scientists say that 64 percent of cancers of the oral cavity, head, and neck in the U.S. are caused by human papillomavirus (HPV), which is commonly spread via oral sex, NPR reported. The more oral sex you have - and the more oral sex partners you have - the greater the risk of developing these potentially deadly cancers. "An individual who has six or more lifetime partners - on whom they've performed oral sex - has an eightfold increase in risk compared to someone who has never performed oral sex, Ohio University's Dr. Maura Gillison, said at a recent scientific meeting, according to NPR. It's news that might alarm some parents, who worry about adolescents' appetite for oral sex. "Today's teens consider oral sex to be casual, socially acceptable, inconsequential, and significantly less risky to their health than 'real' sex," Dr. Gillison and colleagues said in a written statement released in conjunction with the meeting. Teens simply think oral sex is "not that a big a deal," Dr. Bonnie Halpern-Felsher, professor of pediatrics at the University of California, San Francisco, told NPR. "Parents and health educators are not talking to teens about oral sex. Period." But simply needling teens about the risks posed by oral sex and HPV - the same virus that causes cervical cancer - is no substitute for literally giving them the needle. "When my patients ask [...]

Oral Cancer Foundation News Team - A2011-02-24T10:23:55-07:00February, 2011|OCF In The News, Oral Cancer News|

Virus passed during oral sex tops tobacco as throat cancer cause

Source: www.npr.org Author: Peggy Girshman If you're keeping score, here's even more evidence that HPV causes oral, head and neck cancers and that vaccines may be able to prevent it. Researchers studying the human papilloma virus say that in the United States HPV causes 64 percent of oropharynxl cancers. In the rest of the world, tobacco remains the leading cause of oral cancer, Dr. Maura Gillison of Ohio State University told a meeting of the American Association for the Advancement of Science this past weekend. And the more oral sex someone has had — and the more partners they've had — the greater their risk of getting these cancers, which grow in the middle part of the throat. "An individual who has six or more lifetime partners — on whom they've performed oral sex – has an eightfold increase in risk compared to someone who has never performed oral sex," she said. The recent rise in oropharnx cancer is predominantly among young, white men, she noted, though she says no one has figured out why yet. About 37,000 people in the United States were diagnosed with oral cancer in 2010, according to the Oral Cancer Foundation. People with HPV-related throat cancer are more likely to survive their cancer than those who were heavy smokers or drinkers, the other big risk factors. The message may be more critical for teens according to Bonnie Halpern-Felsher, professor of pediatrics at the University of California, San Francisco. She has studied 600 adolescents over 10 [...]

Oral Cancer Foundation News Team - A2011-02-24T10:24:37-07:00February, 2011|Oral Cancer News|

Revealed: oral sex is ‘bigger cause of throat cancer than tobacco’

Source: www.dailymail.co.uk Author: staff A virus spread during oral sex is now the main cause of throat cancer in people under 50, scientists have warned. They say the human papilloma virus spread during unprotected sex is to blame for a disturbing rise in potentially deadly oral cancers in the last few decades. Doctors have called for boys to be vaccinated against HPV just like teenage girls to stop the spread of the disease. HPV is best known as the cause of around 70 per cent of cervical cancers. Since 2008, girls have been vaccinated against the virus aged 12 and 13 in schools. However, it can also cause warts, verrucas and other cancers. Cancers of the mouth and oropharynx - the top of the throat - used to be mainly diagnosed in older men who drink or smoke. But increasingly, it is being seen in younger men. Prof Maura Gillison of Ohio State University in Columbus said the sexually transmitted HPV was a bigger cause of some oral cancers than tobacco. She said: 'We don’t know from strict scientific evidence whether the vaccine will protect from oral HPV infections that lead to cancer. Those of us in the field are optimistic it will – the vaccines in every anatomical site looked at so far have been shown to be extraordinarily effective, about 90 per cent effective, at preventing infections.' 'When one of my patients asks whether or not they sound vaccinate their sons, I say certainly.' Girls aged 12 and [...]

Oral Cancer Foundation News Team - A2011-02-21T12:58:57-07:00February, 2011|Oral Cancer News|

Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus–associated oropharyngeal cancer

Source: jco.ascopubs.org Authors: Luc G.T. Morris et al. Purpose: Patients with head and neck squamous cell carcinoma (HNSCC) are at elevated risk of second primary malignancies (SPM), most commonly of the head and neck (HN), lung, and esophagus. Our objectives were to identify HNSCC subsite-specific differences in SPM risk and distribution and to describe trends in risk over 3 decades, before and during the era of human papillomavirus (HPV) –associated oropharyngeal SCC. Methods: Population-based cohort study of 75,087 patients with HNSCC in the Surveillance, Epidemiology, and End Results (SEER) program. SPM risk was quantified by using standardized incidence ratios (SIRs), excess absolute risk (EAR) per 10,000 person-years at risk (PYR), and number needed to observe. Trends in SPM risk were analyzed by using joinpoint log-linear regression. Results: In patients with HNSCC, the SIR of second primary solid tumor was 2.2 (95% CI, 2.1 to 2.2), and the EAR was 167.7 cancers per 10,000 PYR. The risk of SPM was highest for hypopharyngeal SCC (SIR, 3.5; EAR, 307.1 per 10,000 PYR) and lowest for laryngeal SCC (SIR, 1.9; EAR, 147.8 per 10,000 PYR). The most common SPM site for patients with oral cavity and oropharynx SCC was HN; for patients with laryngeal and hypopharyngeal cancer, it was the lung. Since 1991, SPM risk has decreased significantly among patients with oropharyngeal SCC (annual percentage change in EAR, −4.6%; P = .03). Conclusion: In patients with HNSCC, the risk and distribution of SPM differ significantly according to subsite of the index cancer. Before [...]

Oral Cancer Foundation News Team - A2011-02-19T10:13:38-07:00February, 2011|Oral Cancer News|

Quadrivalent HPV vaccine may be effective in young men

Source: www.medscape.org Author: Laurie Barclay, MD; Charles P. Vega, MD Quadrivalent human papillomavirus (HPV) vaccine may prevent infection with HPV types 6, 11, 16, and 18 and the development of related external genital lesions in young men 16 to 26 years old, according to the results of a randomized, placebo-controlled, double-blind trial reported in the February 3 issue of the New England Journal of Medicine. "Infection with ...HPV and diseases caused by HPV are common in boys and men," write Anna R. Giuliano, PhD, from the Risk Assessment, Detection, and Intervention Program, H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and colleagues. "We report on the safety of a quadrivalent vaccine (active against HPV types 6, 11, 16, and 18) and on its efficacy in preventing the development of external genital lesions and anogenital HPV infection in boys and men." The study sample consisted of 4065 healthy boys and men, aged 16 to 26 years, enrolled from 18 countries. The primary efficacy goal was to demonstrate that use of the quadrivalent HPV vaccine was associated with a lower incidence of external genital lesions related to HPV-6, 11, 16, or 18. The investigators used a per-protocol population, in which participants received all 3 vaccinations and had tested negative for relevant HPV types at enrollment, and an intent-to-treat population, in which participants received vaccine or placebo, regardless of baseline HPV status. In the intent-to-treat population, there were 36 external genital lesions in the vaccine group and 89 in the [...]

Oral Cancer Foundation News Team - A2011-02-15T13:47:01-07:00February, 2011|Oral Cancer News|

Assessment of human papillomavirus in lung tumor tissue

By: Journal of the National Cancer Institute Affiliations of authors: Division of Cancer Epidemiology and Genetics, NCI/NIH/DHHS, Bethesda, MD (JK, MR, AKC, AMG, AH, PRT, SW, MTL, NEC); Department of Internal Medicine, Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH (MLG, HS); DDL Diagnostic Laboratory, Voorburg, the Netherlands (L-JVD, WGVQ, LS); EPOCA Research Center, Department of Occupational and Environmental Health, Università degli Studi di Milano, Milan, Italy (LT, PAB); Epidemiology Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy (LT, PAB) Background Lung cancer kills more than 1 million people worldwide each year. Whereas several human papillomavirus (HPV)–associated cancers have been identified, the role of HPV in lung carcinogenesis remains controversial. Methods We selected 450 lung cancer patients from an Italian population–based case–control study, the Environment and Genetics in Lung Cancer Etiology. These patients were selected from those with an adequate number of unstained tissue sections and included all those who had never smoked and a random sample of the remaining patients. We used real-time polymerase chain reaction (PCR) to test specimens from these patients for HPV DNA, specifically for E6 gene sequences from HPV16 and E7 gene sequences from HPV18. We also tested a subset of 92 specimens from all never-smokers and a random selection of smokers for additional HPV types by a PCR-based test for at least 54 mucosal HPV genotypes. DNA was extracted from ethanol- or formalin-fixed paraffin-embedded tumor tissue under strict PCR clean [...]

Oral Cancer Foundation News Team - A2011-02-04T18:07:12-07:00February, 2011|Oral Cancer News|

Does chocolate hold the key to cure HPV?

Source: Yahoo News Indulgent chocolate treats may be the best-known and most widely appreciated product of the cacao tree, but new scientific research from New York Based Cacao Biotechnologies is uncovering potential new applications for the antioxidant-rich beans which could spur an innovative approach to treating human papillomavirus (HPV), a precursor to cervical cancer. The human papillomavirus is the most common sexually transmitted infection (STI) in the United States, with an estimated 24 million active cases and 5.5 million new cases each year, according to the National Cancer Institute. HPV is the leading cause of cervical cancer in woman with more than 12,000 cases reported in the U.S. each year. HPV vaccines approved by the Food and Drug Administration are available, but they are not a cure and they can’t effectively prevent all strains of HPV infection in those who are sexually active. Existing vaccines are only proven effective against a small number of high-risk, cancer-causing HPV strains and are not free of serious side effects including convulsions and paralysis. While condoms can reduce the risk of HPV infection, the virus can still be transmitted simply through skin contact of areas not covered by the condom. Vaccination will not cure someone who is already infected with the virus, so even with massive public health education campaigns, HPV will not soon be eradicated because it is so widely spread in the adult population. According to Penny Hitchcock, Chief of the Sexually Transmitted Diseases Branch of the U.S. government’s National Division of [...]

Oral Cancer Foundation News Team - A2011-02-04T12:16:39-07:00February, 2011|Oral Cancer News|